Suppl. Fig 5

A

**

Responders (n=21)
Non-responders (n=11)

Proportion (%)

PIK3CA STK11 FBXW7 PTEN BAP1 MED12 TP53 ERBB2 SMAD4 SMARCA4 CDK12 ERBB3 KMT2A SETBP1

B

PFS ≥ 6 months (n=21)
PFS < 6 months (n=8)

Proportion (%)

PIK3CA STK11 PTEN FBXW7 BAP1 MED12 TP53 ERBB2 SMAD4 SMARCA4 CDK12 ERBB3

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)